kabutan

Solasia Pharma K.K.(4597) Summary

4597
TSE Growth
Solasia Pharma K.K.
33
JPY
-1
(-2.94%)
Dec 5, 11:30 am JST
0.21
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
32.7
Dec 5, 11:27 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.78
Yield
ー%
Margin Trading Ratio
2.75
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
33 JPY 0.21 USD
Previous Close Dec 4
34 JPY 0.21 USD
High Dec 5, 9:00 am
34 JPY 0.21 USD
Low Dec 5, 9:10 am
32 JPY 0.20 USD
Volume
22,753,000
Trading Value
0.75B JPY 4.84M USD
VWAP
32.99 JPY 0.21 USD
Minimum Trading Value
3,300 JPY 21 USD
Market Cap
8.59B JPY 0.06B USD
Number of Trades
171
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
402
1-Year High Jun 27, 2025
2,772
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 2,243,300 24,394,500 10.87
Nov 21, 2025 4,412,600 26,143,800 5.92
Nov 14, 2025 4,398,800 25,774,300 5.86
Nov 7, 2025 3,126,900 26,472,600 8.47
Oct 31, 2025 1,816,400 26,610,200 14.65
Company Profile
Solasia Pharma K.K. is a biopharmaceutical venture company focused on cancer and malignant tumor drug discovery. The company engages in the development of pharmaceuticals and medical devices, with a primary focus on clinical development.
Sector
Pharmaceuticals
Solasia Pharma K.K. operates as a biopharmaceutical venture company specializing in the oncology field, developing both pharmaceuticals and medical devices. The company primarily concentrates on clinical development, introducing promising new drug candidates and conducting trials in Japan and other Asian countries. With multiple development pipelines, Solasia focuses on treatments for malignant tumors and supportive care medications. Their product portfolio includes darinaparsin for peripheral T-cell lymphoma, a transdermal granisetron preparation for preventing chemotherapy-induced nausea and vomiting, and a medical device aimed at alleviating pain from oral mucositis. The company's business model encompasses the entire process from clinical development to regulatory submission and out-licensing of marketing rights. Solasia aims to generate revenue through out-licensing to pharmaceutical companies, which includes sales revenue, milestone payments, and royalty income.